Fig. 4

Effect of bi- and trifunctional nanodrugs alone or in combination with doxorubicin (Doxo). WEHI-164 tumor-bearing mice were treated (i.v.) at the indicated times after tumor implantation (arrows) with the indicated doses of iso1Au/TNF, iso1Au/IL12, iso1Au/TNF + IL12 and Doxo (150 µg). The indicated doses correspond to immunoreactive IL12, as detected by ELISA, or bioactive TNF, as determined by the L–M cytolytic assay. a Tumor volume (upper panels) and body weight changes (lower panels) (mean ± SE, 4–6 mice per group). b Kaplan–Meier curves of Doxo alone and in combination with iso1Au/TNF or iso1Au/TNF + IL12. The cumulative data of the two experiments performed with iso1Au/TNF + IL12 (a right panels) are reported. *P < 0.05; **P < 0.01, ***P < 0.001, ****P < 0.0001 by log-rank (Mantel-Cox) test